PharVision Advisers’s Sanofi SNY Stock Holding History

PharVision Advisers’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,121	Closed	-$394K	–	567
2025 Q4	$394K	Buy	+8,121	New	+$403K	0.2%	132

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PharVision Advisers's SNY Position: Q1 2026 in Review

PharVision Advisers sold out of Sanofi (SNY) in Q1 2026, closing a stake of 8,121 shares — an estimated $394K sold.

PharVision Advisers first reported a position in SNY in Q4 2025 and held it in 1 quarter. The position peaked at $394K in Q4 2025. 737 funds tracked by Wall St. Rank hold SNY as of Q1 2026.

PharVision Advisers reported no remaining Sanofi position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 8,121 Sanofi shares in Q1 2026, an estimated $394K.
PharVision Advisers first reported a position in Sanofi in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Sanofi position peaked at $394K in Q4 2025.
737 funds tracked by Wall St. Rank held Sanofi as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.